HighTide Therapeutics

Exploring new possibilities in obesity management! HighTide Therapeutics will share new HTD1801 findings at #ObesityWeek 2026, highlighting its potential for improved weight management. #OW2026 #ObesityResearch #ObesityScience #MetabolicHealth #HTD1801 #HighTideTherapeutics

We are excited to present new findings on #HTD1801 at #ASN2026. HTD1801 targets the AMPK–NLRP3 axis and demonstrates potent inhibitory activity against cyst expansion in ADPKD, highlighting its potential as a disease-modifying therapy. #KidneyWk #ADPKD #hightidetherapeutics

Looking forward to #KidneyWk 2026 in Denver, where HighTide Therapeutics will present new preclinical data on HTD1801, highlighting its therapeutic potential in autosomal dominant polycystic kidney disease (ADPKD). #ASN2026 #kidneyweek2026 #ADPKD #HTD1801 #hightidetherapeutics

HighTide Therapeutics’ HTD1801 Featured in Two Articles Published in Diabetes Care, Further Highlighting the Clinical Value of China-Originated Innovation in T2DM Treatment #htd1801 #T2DM #ckmdiseases

ESC 2026 | HighTide Therapeutics Presents HTD1801 as a Multisystem CKM Therapy in Oral Presentation Dr. Filip Surmont presented data from multiple HTD1801 studies, highlighting HTD1801’s potential as a multisystem CKM therapy. #ESC2026 #htd1801 #ckmtherapy #ESC2026

HighTide Therapeutics (2511.HK) will participate in ESC Congress 2026 in Munich, August 28–31. Dr. Filip Surmont will deliver an oral presentation highlighting HTD1801 as a multisystem CKM therapy. 🗓️ August 28 | 8:15 a.m. CEST 📌 Presentation 86063 #ESC2026

HighTide Therapeutics Announces Publication of Phase III Results of HTD1801 in NEJM Evidence HTD1801 delivers sustained glycemic control and broad benefits across the CKM spectrum, supported by favorable long-term safety.

ADA 2026 l HighTide Therapeutics Presents Data from Three HTD1801 Studies, Highlighting Foundational Therapeutic Potential in CKM Diseases ✅ Long-term extension data, ✅ Head-to-head Phase III results, ✅ Combination data in weight management #HTD1801 #ADA2026 #CKMDiseases

ERA2026 l HighTide Therapeutics Presents New Findings Supporting HTD1801's Renoprotective Potential in Oral Presentation Targeting the AMPK-NLRP3 axis, HTD1801 continues to show promising renoprotective potential in CKD and other renal diseases.

Looking ahead to the 63rd Congress of the European Renal Association (ERA 2026) HighTide Therapeutics will present new findings on HTD1801 and its renoprotective potential. 📍Glasgow, UK 🗓 June 4, 2026 🎤Oral Presentation #2243 #ERA2026 #KidneyResearch #HTD1801

HighTide Therapeutics Announces NDA Acceptance for HTD1801 Highlights: • 3 Phase III trials met endpoints • Benefits across the CKM spectrum • First-in-class New Molecular Entity #HTD1801 #Biopharma #ClinicalTrials #DrugDevelopment #Diabetes 🔗hightidetx.com

HighTide Therapeutics (2511.HK) names Dr. Filip Surmont as Chief Medical Officer, strengthening its global clinical development and CKM disease portfolio. #biotech #PharmaLeadership #clinicaldevelopment #HealthcareInnovation #PharmaNews #healthcare

🌐HighTide Therapeutics Presents Renal Data for HTD1801, Reinforcing Its Potential as a Foundational CKM Therapy at CVCT Forum. Follow us for more updates. #HightideTherapeutics #CVCT2025 #HTD1801 #CKM #KidneyHealth #Cardiometabolic #ClinicalResearch

Post 🌐HighTide will present multifaceted CKM evidence for HTD1801 at CVCT 2025! 🎤Late-Breaking Oral Presentation Dec 9 | 08:30–10:30 ET 📌 Poster Presentation Dec 8–10 📍 Washington DC, US We look forward to sharing more insights from the event. @HighTideThera #HTD1801

HighTide Therapeutics’ HTD1801 Achieves Greater HbA1c Reduction & Superior Cardiometabolic Marker Improvement Versus Dapagliflozin in Phase III Head-to-Head Trial ✔ Greater HbA1c reduction ✔ Superior cardiometabolic improvements versus dapagliflozin ✔ Favorable safety profile

🚨 Late-Breaking @ASNKidney 2025! New data from @HighTideThera show #HTD1801 improves eGFR in patients with mild renal impairment — the first clinical evidence of potential kidney benefit in early #CKD. 📍Poster #TH-PO1190 | 🗓️Nov 6 | 10AM–12PM

📣 Late-Breaking at #ASN2025! Excited to share new evidence of kidney benefit with #HTD1801 in patients with mild renal impairment. 📅 Nov 6 | 🕙 10AM–12PM (CT) 📍 Houston, TX 🧪 Poster TH-PO1190 Join us at #KidneyWeek as we advance innovation in #renalhealth.

Major Milestone for HighTide Therapeutics Breakthrough in #Type2Diabetes! HighTide has completed two Phase 3 trials — SYMPHONY-1 & SYMPHONY-2 — for #HTD1801, a first-in-class anti-inflammatory metabolic modulator, showing durable 52-week efficacy & multi-system benefits.